ReviewFrontiers in immunology2026
Peripheral-central inflammatory crosstalk in Alzheimer's disease: immunometabolic functions of circulating soluble metabolites under dynamic blood-brain barrier states.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunometabolic dysregulation orchestrating bidirectional peripheral-central inflammatory crosstalk has been increasingly recognized as a contributor to Alzheimer's disease (AD) pathogenesis, challenging the conventional view of AD as an isolated central disorder dominated by amyloid-beta (Aβ) and tau pathology. However, although central immune-metabolic disturbances are well established, this perspective largely overlooks peripherally derived regulatory signals from systemic circulation. Classical peripheral-to-central pathways, such as immune cell infiltration and cytokine leakage, depend on overt blood-brain barrier (BBB) damage and cannot account for the latent neuroinflammation characteristic of the prodromal stage, when neurovascular units remain largely intact. To address this gap, we review recent advances on circulating soluble metabolites (<500 Da)-key immunometabolic mediators linking systemic disturbances to central lesions-and organize them into three groups by biosynthetic origin (a heuristic, non-taxonomic classification): peripheral immune-derived, gut microbiota-derived, and systemic host metabolic intermediates. We outline the transmembrane transport shifts associated with progressive BBB dysfunction and the downstream intracellular cascades-such as mitochondrial redox disturbance, mTOR-NLRP3 inflammasome activation, and histone epigenetic remodeling-that mediate this crosstalk. Importantly, although these proposed associations are mechanistically informative, they remain largely unsupported by direct human evidence and require further validation in large AD cohorts; nevertheless, several individual metabolite biomarkers already show consistent clinical association. This framework clarifies the multi-stage immunometabolic axis and may inform the development of ultra-early fluid biomarkers and peripheral-targeted immunometabolic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.